Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AstraZeneca plc (AZN) vs KraneShares Electric Vehicles and Future Mobility (KARS) Price & Performance

AstraZeneca plcTrade
KraneShares Electric Vehicles and Future MobilityTrade

Price performance (Past 24H)

Key statistics

AstraZeneca plc vs KraneShares Electric Vehicles and Future Mobility — how do they compare? AstraZeneca plc trades at $158.69 (market cap $248.14B), while KraneShares Electric Vehicles and Future Mobility trades at $30.99. The key difference: AstraZeneca plc pays a 2.01% dividend while KraneShares Electric Vehicles and Future Mobility pays none, and KraneShares Electric Vehicles and Future Mobility is trading nearer its 52-week high, AstraZeneca plc nearer its low. Which is the better fit depends on your goals.

AZNKARS
Market Cap
$248.14B
Sector
HealthSector/Thematic
52-Week High
$209.48$38.01
52-Week Low
$147.06$25.59
Enterprise Value
$275.41B
Dividend Yield
2.01%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AstraZeneca plc

AstraZeneca (AZN) trades at $157.39, down 2.79% amid bearish technical signals and merger speculation. The company demonstrates strong fundamentals with revenue growth to $58.74B in 2025 and a net income margin of 17.02%. Recent earnings have consistently beaten estimates, and analyst consensus is positive with 47.5% buy ratings. However, news of potential merger talks with Bristol Myers Squibb and a related legal investigation have introduced volatility.

The outlook is mixed; solid profitability and growth support long-term value, but near-term price pressure from technical indicators and merger uncertainty presents a cautious entry point. Key risks include deal execution challenges and integration complexities should a merger proceed.

KraneShares Electric Vehicles and Future Mobility

KARS trades at $30.99, down 0.42% on the day, with a bullish technical signal driven by moving averages and oscillators. The stock faces resistance near $31-$32, while support lies at $30-$29. Recent news highlights global EV sales growth, with China targeting 30% NEV fleet by 2030 and Europe seeing demand surges from high fuel prices, though U.S. adoption lags.

The outlook for KARS is supported by EV industry tailwinds, but risks include competitive pressures from Chinese automakers and regulatory delays. Analyst sentiment is mixed, with technical indicators suggesting near-term consolidation. Institutional interest may hinge on sustained EV adoption trends and execution against growth targets.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AstraZeneca plc

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.

Read more on AZN

About KraneShares Electric Vehicles and Future Mobility

KARS invests in the global electric vehicle ecosystem and future mobility. It tracks the Bloomberg Electric Vehicles Index, providing exposure to EV manufacturers, battery technology, and lithium miners like Tesla, BYD, and Albemarle.

Read more on KARS